WO1993008299A1 - Preparation of recombinant borrelia proteins - Google Patents
Preparation of recombinant borrelia proteins Download PDFInfo
- Publication number
- WO1993008299A1 WO1993008299A1 PCT/US1992/008697 US9208697W WO9308299A1 WO 1993008299 A1 WO1993008299 A1 WO 1993008299A1 US 9208697 W US9208697 W US 9208697W WO 9308299 A1 WO9308299 A1 WO 9308299A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- plasmid
- ospa
- gene
- lipoprotein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 115
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 79
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 40
- 241000589968 Borrelia Species 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title description 5
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 70
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 66
- 239000003599 detergent Substances 0.000 claims abstract description 47
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 30
- 108700006640 OspA Proteins 0.000 claims abstract description 19
- 229920004929 Triton X-114 Polymers 0.000 claims abstract description 14
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims abstract description 9
- 239000013600 plasmid vector Substances 0.000 claims abstract description 6
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 33
- 101150045801 ospA gene Proteins 0.000 claims description 31
- 239000012071 phase Substances 0.000 claims description 31
- 241000588724 Escherichia coli Species 0.000 claims description 25
- 238000000746 purification Methods 0.000 claims description 19
- 229940099789 ospa protein Drugs 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 238000005191 phase separation Methods 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 241000701832 Enterobacteria phage T3 Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 7
- 230000014616 translation Effects 0.000 abstract description 4
- 238000004440 column chromatography Methods 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 238000003149 assay kit Methods 0.000 abstract 1
- 101710105714 Outer surface protein A Proteins 0.000 description 75
- 235000018102 proteins Nutrition 0.000 description 41
- 241000699670 Mus sp. Species 0.000 description 26
- 101150107995 ACA1 gene Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 230000005847 immunogenicity Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 229920002271 DEAE-Sepharose Polymers 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 150000002632 lipids Chemical group 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 241000589970 Spirochaetales Species 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000012130 whole-cell lysate Substances 0.000 description 4
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108090000233 Signal peptidase II Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 125000000926 ampicilloyl group Chemical group [H]N([H])[C@@]([H])(C(=O)N([H])[C@]1([H])C(=O)N2[C@]1([H])SC(C([H])([H])[H])(C([H])([H])[H])[C@]2([H])C(*)=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000005354 penicillin allergy Diseases 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001799 protein solubilization Methods 0.000 description 1
- 230000007925 protein solubilization Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical group [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the preparation of recombinant Borrelia lipoproteins, particularly the outer surface protein A (OspA) of Borrelia burqdorferi, the spirochete responsible for Ly e disease.
- OspA outer surface protein A
- Lyme disease is a zoonosis caused by the tick-borne spirochete Borrelia burqdorferi.
- the spirochete can cause serious dermatological, arthritic, neurological and other pathological disorders in an infected host.
- Lyme disease has become a serious epidemiological concern, particularly in North America, but also elsewhere in the world.
- the paper describes the preparation of two plasmids, pET9-OspA and pET9- preOspA, the former containing a polymerase chain reaction (PCR)-amplified DNA sequence coding for a recombinant truncated version of OspA, and the latter containing a PCR-amplified DNA sequence coding for the full-length, wild-type OspA. Both sequences are expressed from the bacteriophage T7 ⁇ 10 promoter.
- the primary translation product of the full-length gene contains a hydrophobic N-terminal leader sequence, which is a substrate for the attachment of lipid moiety to the sulfhydryl side chain of the adjacent cysteine residue.
- the protein translated from the truncated gene is not lipidated, and is soluble in aqueous solution.
- Expression of the soluble, truncated derivative of OspA is said to overcome certain problems said to be associated with expressing recombinant versions of the full-length wild-type Borrelia burgdorferi lipoproteins using E. coli. namely that the protein has poor solubility properties, due to the association of the protein with the outer cell membrane of the host during expression, requiring the use of detergents to effect separation of the protein and difficult purification procedures.
- the plasmids were transferred to an expression strain of E. coli. namely BL21(.DE3) (pLysS) (a host strain containing a chromosomal copy of the gene for T7 RNA polymerase under control of the inducible lacUVS promoter and a pACYC184 based plasmid pLysS, which produces low levels of T7 lysozyme) .
- pLysS a host strain containing a chromosomal copy of the gene for T7 RNA polymerase under control of the inducible lacUVS promoter and a pACYC184 based plasmid pLysS, which produces low levels of T7 lysozyme
- plasmid pET9- preOspA was found to produce relatively smaller amounts of inducible protein than plasmid pET9-0spA.
- the latter product was found to be soluble in the absence of detergent while the former required treatment with
- OspA (refs. 1, 8) .
- the antigen used in these studies was a fusion protein containing a large domain of glutathione- S-transferase at the amino terminus of OspA. This fusion protein is unlikely to be a substrate for a post- translational lipid attachment.
- the ability of this antigen to induce a protective response in these studies may be due to the fact that the antigen was delivered in Freund's complete adjuvant, with multiple secondary doses in Freund's incomplete adjuvant (refs. 1, 8), or in the form of live or killed whole E. coli expressing the fusion protein (ref. 9) .
- this prior activity reference also is made to published International application WO 92/00055.
- the recombinant protein encoded by the full length ospA gene in unadjuvanted or alum-absorbed form, exhibits an immunogenicity which is not shown by the corresponding recombinant OspA protein lacking the attached lipid.
- This difference in immunogenicity has been shown not to be due to any difference between the antigenicity of the two proteins.
- the present invention represents the first disclosure of which the inventors are aware of enhancement of the immunogenicity of a large protein antigen by expression of a bacterial lipoprotein.
- the present invention provides, in one aspect, a novel, simple and effective manner of producing a highly- purified immunologically-e fective " recombinant protein encoded by the full-length wild-type B. burgdorferi ospA gene and other full-length Borrelia lipoproteins encoded by the respective genes.
- the recombinant protein exhibits an immunogenicity which is equal to that of the native protein.
- the present invention employs selective separation of the recombinant lipoprotein from other cellular constituents using particular detergents. The procedure of the present invention enables the perceived prior art problems associated with production of the full-length OspA protein to be overcome, while providing a product having enhanced immunogenicity.
- a highly-purified immunologically-effective recombinant protein which is encoded by a full-length wild-type Borrelia lipoprotein gene, particularly the B.burgdorferi ospA gene, and which is formed recombinantly from a host organism transformed by a plasmid containing the gene.
- Such novel protein forms a further aspect of the present invention.
- novel protein product provided herein is useful in vaccines against infection by Borrelia organisms, particularly those causing Lyme disease, and such vaccines, comprising an immunologically-effective amount of the protein, particularly that encoded by the full- length wild-type B. burgdorferi os A gene, constitute an additional aspect of the invention.
- a method of immunization of a mammal against infection by Borrelia organisms, particularly those causing Lyme disease by administering an immunologically- effective amount of the protein, particularly that encoded by the full-length wild type B. burgdorferi ospA gene, in the absence of adjuvant.
- novel proteins also may be used as immunodiagnostic agents for the detection of antibodies against infection of a host by a Borrelia organism, particularly that causing Lyme disease, and hence the presence of such infection.
- immunodiagnostic agents for the detection of antibodies against infection of a host by a Borrelia organism, particularly that causing Lyme disease, and hence the presence of such infection.
- purified immunologically-effective recombinant protein encoded by the full-length ospA gene from several different specific strains of B. burgdorferi. specifically the B31, ACA1 and Ip90 strains.
- ospA genes which dif er in nucleotide sequence from the sequences of these specific genes by at the most a few nucleic acids, resulting in gene products which differ at most by a few amino acids from those produced by the actual B31, ACA1 and Ip90 strain ospA genes.
- genes and gene products are encomposed herein within the B31, ACA1 and Ip90 families of strains.
- Figure 1 shows the PCR oligonucleotides used in cloning the B-31, ACA1 and Ip90 full-length ospA gene of B. burgdorferi into the pET9a expression vector;
- Figure 2 illustrates the cloning strategy for inserting the full-length ospA gene into the pET9a expression vector so as place the ospA gene under control of the T7 ⁇ 10 promoter, to form pOAl from the B31 gene, pOA9 from the ACA1 gene and pOAlO from the Ip90 gene;
- Figure 3 is a predicted restriction map of plasmid pOAl
- Figure 5 shows the PCR nucleotides used in cloning the B-31, ACA1 and Ip90 full-length OSPA gene of B burgdorferi into the pCMBl expression vector;
- Figure 6 illustrates the cloning strategy for inserting the full-length ospA gene into the pCMBl expression vector, so as to place the ospA gene under the control of the Trc promoter, to form pOA5 from the B31 gene, pOA7 from the ACA1 gene and pOA8 from the Ip90 gene;
- Figures 7A, 7B and 7C show a time course of induction with ITPG of OspA in two host strains containing pOAl ( Figure 7A) , and a host strain containing pOA5 (Figure 7B) and pOA6 ( Figure 7C) ;
- Figures 8A, 8B and 8C are flow charts showing, respectively, the cell growth and lysis, the detergent extraction and the purification steps involved in the production and purification of recombinant full-length OspA from E. coli in accordance with one embodiment of the invention;
- FIG 11 illustrates Triton X-114 phase partitioning of lipoprotein and non-lipoprotein for pOAl and pOA2, in which bacteria containing pOAl expressing OspA lipoprotein or pOA2 expressing OspA non-lipoprotein were grown to mid- log phase and induced with ITPG for 2 hours for pOAl and 4 hours for pOA2. After centrifugation, cells were resuspended and lysis was effected by freezing and thawing. Triton X-114 was added and phase partitioning was produced by heating to 37°C. An equal aliquot of each fraction was electrophoresed on 4 to 20% SDS-PAGE gel, and the gel was stained with Coomassie Brilliant Blue. The fractions are molecular weight markers (M) , whole lysate (W) , aqueous phase (A) , detergent phase (D) , and insoluble pellet (P) for pOAl and pOA2 as indicated;
- M molecular weight markers
- Figures 12A, 12B and 12C illustrate purification of OspA lipoprotein produced from pOAl ( Figure 12A) , from pOA9 and pOAlO ( Figure 12B) and from pOA5, pOA7 and pOA8 ( Figure 12 C) , where an aliquot of each fraction was electrophoresed on a 4 to 20% SDS-PAGE gel and the gel was stained with Coomassie Brilliant Blue.
- Figure 12A lane 1, low molecular weight markers; lane 2, whole lysate; lane 3, detergent phase; lane 4, DEAE-Sepharose; and lane 5, S-Sepharose elution;
- CL whole cell lysate,
- Figure 14 shows the IgG serum titres of mice given a boost four weeks after primary injection with 10 ⁇ g of the purified full-length OspA and B. burgdorferi fraction of Figure 13, with an ELISA assay being ' performed with 100 ng purified OspA in the solid phase, mouse serum as the first antibody and goat anti-mouse IgG conjugated to alkaline phosphatase as the second antibody;
- Figures 15A to 15E contain a graphical depiction of the dose response of mice to lipoprotein.
- Figure 15A shows the dose response of C3H/He mice to unadsorbed lipoprotein;
- Figure 15B shows the dose response of BALB/c mice to unadsorbed lipoprotein;
- Figure 15C shows the dose response of C3H/He mice to lipoprotein adsorbed to alum;
- Figure 15D shows the dose response of CH3/He mice to unadsorbed lipoprotein;
- Figure 15E shows the dose response CH3/He mice to non-lipidated protein. Mice were vaccinated at week 0 with the indicated amount of protein, in PBS except where noted, and boosted with the same vaccine at week 3. Serum IgG titre at week 4 was determined by ELISA using OspA lipoprotein as antigen;
- Figure 16 contains a graphical depiction of the antigenicity of the lipoprotein and non-lipoprotein.
- Figure 17 illustrates the production of plasmids pCMBl and pCMB2.
- This plasmid contains truncated os A of B31 strain.
- All other plasmids contain full-length OSPA of various strains.
- the cloned ospA gene of B. burgdorferi strains ACA1 and Ip90 (as described in reference 10 - N- terminal region of ACA1 and Ip90 is: SEQ ID No: 1; C- terminal region of ACA1: SEQ ID No: 5; C-terminal region of Ip90: SEQ ID No: 6) was used in a PCR reaction with oligonucleotide primer pairs (a) 0spN2 (SEQ ID No: 7) and BZ1 (SEQ ID No: 8) and (b) OspN 2 (SEQ ID No: 7) and pK4 (SEQ ID No: 9) , respectively at the N- and C-terminal ends to form the appropriate amplified fragments, as shown in Figure 1.
- the resulting fragments were cloned into the Ndel and Bam HI sites of the plasmid vector pET9 to place the ospA gene under control of a T7 promoter and efficient translation initiation signals from bacteriophage T7, as seen in Figure 2.
- the pET9 and pLysS plasmids, the bacterial hosts for cloning, growth media and the methods used to direct expression of cloned genes by T7 RNA polymerase have previously been described in U.S. Patent No. 4,952,496 and reference may be had thereto for such description.
- T7 promoter system is one preferred expression system in the present invention
- expression of the full-length ospA gene may be achieved utilizing other expression systems compatible with the host organism, as described below.
- the pET9 expression vector was used since it has a kan gene as its selective marker rather than a bla gene. Consequently, ampicillin is not used during cell growth and hence there is no possibility that an immunogenic ampicilloyl/OspA target protein conjugate can be formed. Such conjugates are believed to be major antigenic determinants in penicillin allergy and may complicate immunological studies.
- the resulting plasmids have been designated pOAl, pOA9 and pOAlO, containing the ospA genes from B31, ACA1 and Ip90 strains of B. burgdorferi respectively.
- the pOAl plasmid is nearly identical to the pET9-preOspA plasmid described by Dunn et al (supra) , except that the oligonucleotides used for the PCR reaction were different in the two cases.
- a predicted restriction map for the plasmid pOAl is shown in Figure 3, while Figure 4 contains the results of various restriction digests of plasmid pOAl, demonstrating that all the predicted sites are present.
- the plasmids pOAl, pOA9 and pOAlO were transformed into the expression strain of E. coli or other suitable host organism.
- the E. coli strain is the T7 expression strain of E. coli. as described in the aforementioned U.S. Patent No. 4,952,496.
- the strain may be the expression strain BL21(DE3) (pLysS) of E. coli. as described above, or E. coli strain HMS174(DE3) (pLysS) .
- the transformed host was grown and protein was induced with isopropyl- ⁇ -D- thiogalactoside (IPTG) .
- FIG. 7A A time course of induction of OspA from plasmid pOAl, following IPTG addition, is shown in Figure 7A. Identical results to those for pOAl were obtained using pOA9 and pOAlO. Synthesis of OspA protein from plasmid pOAl ceased approximately one hour after induction, implying some toxicity of the protein to EL. coli. Nevertheless, the protein production was at an acceptable level of approximately 10 mg/L of cell culture. In addition to the provision of plasmids pOAl, pOA9 and pOAlO and expression of OspA lipoprotein in E.
- Plasmids pOA5 and pOA6 were prepared by cloning a PCR-amplified fragment of ospA from B31 strain into the Ncol and Bam HI sites of plasmid expression vectors pCMBl and pCMB2 while plasmids pOA7 and pOA8 were prepared by cloning a PCR- amplified fragment of OspA from ACA1 strain (pOA7) and from Ip90 strain (pOA8) into the Ncol and Bam HI sites of expression vector pCMBl (see Figure 6 for pOA5, pOA7 and pOA8) .
- the cloned ospA genes of B. burgdorferi strains B31, ACA1 and Ip90 were amplified by PCR reaction using oligonucleotide primer pairs (a) PK3 (SEQ ID No: 10) and C03 (SEQ ID No: 3), (b) PK3 and (SEQ ID No: 10) and BZ1 (SEQ ID No: 8), and (c) PK3 (SEQ ID No: 10) and PK4 (SEQ ID No: 9) , respectively at the N- and C- terminal ends of the respective genes to form the appropriate amplified fragments.
- oligonucleotide primer pairs (a) PK3 (SEQ ID No: 10) and C03 (SEQ ID No: 3), (b) PK3 and (SEQ ID No: 10) and BZ1 (SEQ ID No: 8), and (c) PK3 (SEQ ID No: 10) and PK4 (SEQ ID No: 9) , respectively at the N-
- Plasmids pCMBl and pCMB2 were constructed by digesting plasmid pTrc99a (Pharmacia Catalog No. 27-5007- 01) and a Kanamycin resistance gene (Pharmacia Catalog No. 27-4897-01) , isolating the resulting fragments by the Geneclean procedure, and ligating the fragments together ( Figure 17) .
- Plasmid pTrc99a, 4197 bp contains a strong promoter adjacent to a multiple cloning site, followed by a strong transcription termination signal (rrnB) . Expression of the target gene uses the host cell RNA polymerase, allowing its use in a wide variety of E. coli strains.
- lactose suppressor gene included on the vector.
- lactose repressor protein prevents transcription of the target gene in the absence of the inducer IPTG.
- the kanamycin resistance gene is a linear double stranded 1282 bp DNA fragment containing the gene from the transposon Tn903 flanked by restriction enzyme sites and encodes the enzyme aminoglycoside 3'-phosphotransferase, which confers resistance to kanamycin and neomycin.
- pCMBl 5.5 kb
- pCMB2 contains the kanamycin resistance gene oriented in the opposite direction, such that transcription of the resistance gene and the gene of interest under the control of the Trc promoter result in converging transcripts.
- Restriction enzyme digests of pCMBl and pCMB2 using Smal, Hindlll and BamHI+NcoI showed the exact size fragments predicted.
- the plasmids pOA5 and pOA6 were transformed into the expression strain of E. coli or other suitable organism, preferably the DH5 ⁇ competent cells.
- the transformed hosts were grown and protein was induced with IPTG.
- the time course of induction with pOA5 (Figure 7B) was similar to that for pOAl ( Figure 7A) while the levels of OspA produced by pOA6 ( Figure 7C) was several times lower. Identical results to those for pOA5 were obtained using pOA7 and pOA8.
- the invention is not limited to the employment of Triton X-114 but clearly also includes other materials exhibiting a similar selective solubility for OspA as well as the phase separation property under mild conditions referred to below.
- the mixture is warmed to a mild temperature elevation of about
- phase separation occurs under mild conditions to avoid any denaturing or other impairment of the immunological properties of the protein.
- Triton X-100 mentioned by Dunn et al (ref. 3)
- selective separation of OspA protein is effected, much higher temperatures, about 60 to 65°C, are required to effect phase separation, which is highly disadvantageous with respect to the utility of the product
- Centrifugation of the cloudy mixture results in separation of the mixture into three phases, namely a detergent phase containing 50% or more of the OspA protein and a small amount (approximately 5 wt%) of the bacterial proteins, an aqueous phase containing the balance of the bacterial proteins and a solid pellet of cell residue.
- the detergent phase is separated from the aqueous phase and solid pellet.
- Final purification of the protein is effected on a chromatography column selective for binding bacterial proteins but not OspA, specifically DEAE-Sephacel, DEAE- Sepharose, or other equivalent chromatography material.
- the detergent phase is loaded onto the column and the flow-through, which contains all the purified OspA protein is collected.
- the bound fraction contains all the bacterial proteins in the detergent phase.
- the flow-through fraction is substantially free from liposaccharide (LPS) as indicated by lack of pyrogenicity, as determined by limulus amebo ⁇ yte lysate (LAL) .
- LPS liposaccharide
- LAL limulus amebo ⁇ yte lysate
- the highly purified solution of OspA may be freeze dried or otherwise processed.
- Plasmid pOAl was prepared as described above and used to transform E. coli strains BL21(DE3) (pLysS) (pOAl) and HMS174(DE3) (pLysS) (pOAl) .
- the transformed E. coli was inoculated into LB media with 25 ⁇ g/ml of kanamycin sulfate and 25 ⁇ g/ml of chloramphenicol at a rate of 12 ml of culture for every liter prepped. The culture was grown overnight in a flask shaker at about 37°C.
- the cells were thawed to room temperature (about 20° to 25°C) which causes the cells to lyse.
- DNase I was added to the thawed material to a concentration of 1 ⁇ g/ml and the mixture was incubated for 30 minutes at room temperature, which resulted in a decrease in the viscosity of the material.
- the incubated material was " chilled on ice to a temperature below 10°C and Triton X-114 was added as a 10 wt% stock solution, to a final concentration of 0.3 to 1 wt %.
- the mixture was kept on ice for 20 minutes.
- the chilled mixture next was heated to about 37°C and held at that temperature for 10 minutes.
- the solution turned very cloudy as phase separation occurred.
- the cloudy mixture then was centrifuged at about 20°C for 10 minutes at 12,000 xg, which caused separation of the mixture into a lower detergent phase, an upper clear aqueous phase and a solid pellet.
- the detergent phase was separated from the other two phases and cooled to 4°C, without disturbing the pellet.
- Buffer A namely 50 mM Tris, pH 7.5, 2 mM EDTA and 10 mM NaCl, was added to the cooled detergent phase to reconstitute back to l/3rd the original volume.
- the resulting solution may be frozen and stored for later processing as described below or may be immediately subjected to such processing.
- a DEAE-Sepharose CL-6B column was prepared in a volume of 1 ml/10 ml of detergent phase and was washed with 2 volumes of Buffer C, namely 50 mM Tris pH 7.5, 2 mM EDTA, 1 M NaCl, 0.3 wt % Triton X-100, and then with 4 volumes of Buffer B, namely 50 mM Tris pH 7.5, 2 mM EDTA, 0.3 wt % Triton X-100.
- the detergent phase then was loaded onto the column and the flow-through containing the OspA, was collected.
- the column was washed with 1 volume of Buffer B and the flow-through again was collected.
- the combined flow- through was an aqueous solution of purified OspA, which may be frozen for storage.
- the column may be freed from bacterial proteins for reuse by eluting with 2 volumes of Buffer C.
- Example 3 The procedure of Example 1 was repeated, except that other surfactants were used as well as Triton X-114 to form the detergent phase. The results which were obtained are shown in Figure 9. As may be seen from Figure 9, only Triton X-114 of the detergents tested was able to provide a sufficiently selective solubilization of OspA to permit ready purification by column chromatography.
- Example 3
- Plasmids pOA5 and pOA6 were prepared as described above and used to transform E. coli strain DH5 ⁇ . The protein expression procedure employed in Example 1 was repeated and the time course expression of the OspA lipoprotein by pOA5 was identical to that observed for pOAl while OspA expression by pOA6 was found to be several times lower than by pOA5 ( Figures 7B and 7C) . Purification of the OspA protein was continued in pOA5- expressing cells only.
- the B31 OspA lipoprotein produced by the Trc expression system in this way was purified following the identical procedure to that described in Example 1, with the exception that 0.1 mg/ml of lysozyme was added to the cell pellet after harvesting and the cells were suspended for 30 minutes at room temperature prior to freezing.
- both immunogens elicited a very similar response, that is a weak but detectable primary serum IgG response, with as much as a 100-fold increase in serum titres following the boost.
- serum IgG titres remained stable for at least 6 weeks. In neither case was any significant serum IgM response observed.
- the inhibitory activity of the serum was found to be proportional to the dose of the lipoprotein administered to mice and correlated very well with the results obtained by the ELISA assay for anti-OspA IgG.
- the growth inhibitory titres achieved in mice immunized with 2.5 ⁇ g of OspA lipoprotein in PBS were equal to or greater than those obtained in mice vaccinated with 20 ⁇ g of total B. burgdorferi protein in Freund's complete adjuvant and boosted with total protein in PBS.
- Plasmid pOA2 was prepared in similar manner to that described above for plasmid pOAl, except that primer PET- 18N, having the sequence (SEQ ID No. 11) :
- PET-18N 5' CAG CAT ATG GCT AAG CAA AAT GTT AGC 3' was used together with the C-terminal primer PET-273C, in the PCR reaction to amplify the truncated form of the ospA gene lacking the lipoprotein signal peptide.
- the underlined region in PET-18N is identical to nucleotides 51 to 67 of the coding strand of the OspA gene.
- the plasmid pOA2 was used to transform E. coli strains BL21 (DE3) (pLysS) (pOA2) and HMS174 (DE3) (pLysS) (pOA2) and the truncated OspA protein was expressed from the transformed E. coli, as described in Example 1.
- E. coli strains BL21 (DE3) (pLysS) (pOA2) and HMS174 (DE3) (pLysS) (pOA2) the truncated OspA protein was expressed from the transformed E. coli, as described in Example 1.
- the non-lipidated protein was found to be present in the aqueous phase, as would be expected.
- mice were vaccinated with either the lipoprotein form of OspA formed and isolated as described in Example 1 or the non-lipoprotein form of OspA prepared by Dunn et al (ref. 3) and boosted three weeks later. Sera were collected 1 to 2 weeks following boosting, and assayed by an ELISA using purified OspA lipoprotein as the antigen.
- Figures 15A and 15B show that OspA lipoprotein in PBS induced a strong dose-dependent, secondary IgG response in both C3H/He ( Figure 15A) and BALB/c ( Figure 15B) mice. Little, if any, increase in immunogenicity of the lipoprotein was observed when the protein was absorbed to aluminum hydroxide at a ratio of protein: aluminum of 1:5 by weight prior to injection, as seen from Figure 15C.
- the non-lipoprotein was unable to induce any detectable anti-OspA antibody, even at the highest dose of 2.5 ⁇ g/mouse, as seen in Figure 15E. Even alum-absorbed non-lipoprotein appeared incapable of producing an immune response.
- lipoprotein and non- lipoprotein versions of OspA are indentical in deduced amino acid sequence except for the amino terminal residue which is modified cysteine for the lipoprotein and methionine-alanine for the non-lipoprotein, which strongly suggests that the observed difference in immunogenicity is due to the presence of the lipid moiety.
- Example 7 The inherent antigenicity of the lipidated and non- lipidated OspA also was investigated, to determine whether the difference in immunogenicity observed in Example 7 was due to differences in their inherent antigenicity or to differences in how the immune system recognizes and responds to the two proteins.
- strain-source for OspA protein The effect of strain-source for OspA protein on immunogenicity was observed.
- mice were vaccinated with purified OspA lipoproteins B31, ACAl and Ip90 derived from pOAl, pOA9, pOAlO respectively.
- the mice were vaccinated with 2.5 ⁇ g of protein at week 0, boosted with the same dose at week 3, and bled out at week 4.
- Serum IgG titres at week 4 were determined by an ELISA assay using purified B31, ACAl or Ip90 OspA lipoprotein as the antigen. The titre was determined using the secondary antibody goat anti-mouse IgG.
- the present invention provides a novel and simple procedure to produce a highly- purified immunologically-effective recombinant protein encoded by a full-length wild-type Borrelia lipoprotein gene, particularly the ospA gene of B.burgdorferi. by the use of a detergent to selectively extract the protein from the host strain and subsequent purification of the detergent solution by column chromatography. Modifications are possible within the scope of this invention.
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO:3:
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO:6:
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92922390A EP0620860A4 (en) | 1991-10-18 | 1992-10-16 | Preparation of recombinant borrelia proteins. |
JP5507751A JPH06511154A (en) | 1991-10-18 | 1992-10-16 | Method for producing recombinant Borrelia protein |
AU28011/92A AU676140B2 (en) | 1991-10-18 | 1992-10-16 | Preparation of recombinant borrelia proteins |
CA002121121A CA2121121C (en) | 1991-10-18 | 1992-10-16 | Preparation of recombinant borrelia proteins |
NO19941376A NO310417B1 (en) | 1991-10-18 | 1994-04-15 | Preparation of Recombinant Borrelia Proteins |
FI941749A FI941749A (en) | 1991-10-18 | 1994-04-15 | Preparation of Recombinant Borreali Proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77904891A | 1991-10-18 | 1991-10-18 | |
US779,048 | 1991-10-18 | ||
US88876592A | 1992-05-27 | 1992-05-27 | |
US888,765 | 1992-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993008299A1 true WO1993008299A1 (en) | 1993-04-29 |
Family
ID=27119531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/008697 WO1993008299A1 (en) | 1991-10-18 | 1992-10-16 | Preparation of recombinant borrelia proteins |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0620860A4 (en) |
JP (1) | JPH06511154A (en) |
AU (1) | AU676140B2 (en) |
CA (1) | CA2121121C (en) |
FI (1) | FI941749A (en) |
IL (1) | IL103462A0 (en) |
NO (1) | NO310417B1 (en) |
PT (1) | PT100980B (en) |
WO (1) | WO1993008299A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0588578A1 (en) * | 1992-09-14 | 1994-03-23 | Connaught Laboratories Incorporated | Immunogens |
US5434077A (en) * | 1989-09-19 | 1995-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Borrelia burgdorferi strain 257 |
US5942236A (en) * | 1991-08-15 | 1999-08-24 | Smithkline Beecham Biologicals | Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
WO1999061473A1 (en) * | 1998-05-26 | 1999-12-02 | Smithkline Beecham Biologicals S.A. | Method for purification of borrelia lipoprotein ospa |
WO2000063386A2 (en) * | 1999-04-21 | 2000-10-26 | Boston Medical Center Corporation | Prevention, diagnosis and treatment of lyme disease |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
EP1611897A2 (en) | 1997-11-07 | 2006-01-04 | Protein Sciences Corporation | Whole or disrupted insect cells as adjuvant for antigens |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US8680236B2 (en) | 2000-08-18 | 2014-03-25 | Brookhaven Sciences Associates, Llc | Altered OspA of borrelia burgdorferi |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (en) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | CHEMICAL COMPOUNDS |
DE4015911A1 (en) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | VACCINE AGAINST LYME DISEASE |
ES2092560T5 (en) * | 1989-12-22 | 2004-09-16 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | IMMUNOLOGICALLY ACTIVE PROTEINS OF BORRELIA BURGDORFERI, RELATED TEST CASES AND VACCINE. |
CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
US6113914A (en) * | 1991-08-15 | 2000-09-05 | Smithkline Beecham Biologicals (S.A.) | Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
-
1992
- 1992-10-16 JP JP5507751A patent/JPH06511154A/en active Pending
- 1992-10-16 AU AU28011/92A patent/AU676140B2/en not_active Ceased
- 1992-10-16 PT PT100980A patent/PT100980B/en not_active IP Right Cessation
- 1992-10-16 WO PCT/US1992/008697 patent/WO1993008299A1/en not_active Application Discontinuation
- 1992-10-16 CA CA002121121A patent/CA2121121C/en not_active Expired - Fee Related
- 1992-10-16 EP EP92922390A patent/EP0620860A4/en not_active Withdrawn
- 1992-10-18 IL IL103462A patent/IL103462A0/en unknown
-
1994
- 1994-04-15 FI FI941749A patent/FI941749A/en unknown
- 1994-04-15 NO NO19941376A patent/NO310417B1/en not_active IP Right Cessation
Non-Patent Citations (10)
Title |
---|
Infection and Immunity, Volume 54, No. 1, issued October 1986, T.R. HOWE et al., "Organization of genes encoding two outer membrane proteins of the Lyme disease agent Borrelia burgdorferi within a single transcriptional unit", pages 207-212, see entire document. * |
Infection and Immunity, Volume 56, No., issued February 1988, J.D. RADOLF et al., "Identification and localization of integral membrane proteins of virulent Treponema pallidum subsp. pallidum by phase partitioning with nonionic detergent Triton X-114", pages 490-498, see Materials and Methods. * |
Infection and Immunity, Volume 58, No. 4, issued April 1990, M.E. BRANDT et al., "Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins", pages 983-991, see Material and Methods and Figures 1-2. * |
Journal of Chromatography, Volume 521, No. 2, issued 23 November 1990, K.B. GONDOLF et al., "Isolation of an outer membrane protein complex from Borrelia burgdorferi by n-butanol extraction and high-performance ion-exchange chromatography", pages 325-334, see Figure 4. * |
Nucleic Acids Research, Volume 17, No. 21, issued 1989, R. WALLICH et al., "Cloning and sequencing of the gene encoding the outer surface protein (OspA) of a European Borrelia burgdorferi isolate", page 8864, entire document. * |
Protein Expression and Purification, Volume 1, issued November 1990, J.J. DUNN et al., "Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi; high level expression and purification of a soluble recombinant form of OspA", pages 159-168, see Materials and Methods, page 167, last paragraph and * |
Science, Volume 250, No. 4980, issued 26 October 1990, E. FIKRIG et al., "Protection of mice against the Lyme disease agent by immunizing with recombinant OspA", pages 553-556, see page 553. * |
See also references of EP0620860A4 * |
The Journal of Infectious Diseases, Volume 152, No. 3, issued September 1985, A.G. BARBOUR et al., "Heterogeneity of major proteins in Lyme disease Borrelia: a molecular analysis of North American and European isolates", pages 478-484, see entire document. * |
The Journal of Infectious Diseases, Volume 164, No. 1, issued July 1991, M.M. SIMON et al., "Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice", pages 123-132, see entire document, especially Figures 1 and 4. * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5434077A (en) * | 1989-09-19 | 1995-07-18 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Borrelia burgdorferi strain 257 |
US5686267A (en) * | 1989-09-19 | 1997-11-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenscaften E.V. | Nucleic acid molecule encoding antigen associated with lyme disease |
US5780030A (en) * | 1989-09-19 | 1998-07-14 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Passive vaccine against Lyme disease |
US6613331B1 (en) | 1989-09-19 | 2003-09-02 | Max-Planck-Gessellschaft zur förderung der Wissenschaften e.V. | Vaccine against Lyme disease |
US5942236A (en) * | 1991-08-15 | 1999-08-24 | Smithkline Beecham Biologicals | Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
EP0588578A1 (en) * | 1992-09-14 | 1994-03-23 | Connaught Laboratories Incorporated | Immunogens |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US7179448B2 (en) | 1993-11-01 | 2007-02-20 | Research Foundation Of The State Of New York | Recombinant constructs of Borrelia burgdorferi |
US7605248B2 (en) | 1993-11-01 | 2009-10-20 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
EP1611897A2 (en) | 1997-11-07 | 2006-01-04 | Protein Sciences Corporation | Whole or disrupted insect cells as adjuvant for antigens |
WO1999061473A1 (en) * | 1998-05-26 | 1999-12-02 | Smithkline Beecham Biologicals S.A. | Method for purification of borrelia lipoprotein ospa |
WO2000063386A3 (en) * | 1999-04-21 | 2001-03-29 | Boston Medical Ct Corp | Prevention, diagnosis and treatment of lyme disease |
WO2000063386A2 (en) * | 1999-04-21 | 2000-10-26 | Boston Medical Center Corporation | Prevention, diagnosis and treatment of lyme disease |
US8680236B2 (en) | 2000-08-18 | 2014-03-25 | Brookhaven Sciences Associates, Llc | Altered OspA of borrelia burgdorferi |
US8992936B2 (en) | 2000-08-18 | 2015-03-31 | Research Foundation Of The State University Of New York | Altered OspA of Borrelia burgdorferi |
Also Published As
Publication number | Publication date |
---|---|
NO310417B1 (en) | 2001-07-02 |
CA2121121C (en) | 2003-06-10 |
AU676140B2 (en) | 1997-03-06 |
PT100980A (en) | 1994-01-31 |
CA2121121A1 (en) | 1993-04-29 |
NO941376L (en) | 1994-06-17 |
FI941749A0 (en) | 1994-04-15 |
IL103462A0 (en) | 1993-03-15 |
EP0620860A1 (en) | 1994-10-26 |
EP0620860A4 (en) | 1997-05-02 |
NO941376D0 (en) | 1994-04-15 |
FI941749A (en) | 1994-05-25 |
JPH06511154A (en) | 1994-12-15 |
PT100980B (en) | 1999-07-30 |
AU2801192A (en) | 1993-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fairweather et al. | Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli | |
Dunn et al. | Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA | |
US5571718A (en) | Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7 | |
US7605248B2 (en) | Recombinant constructs of Borrelia burgdorferi | |
US8992936B2 (en) | Altered OspA of Borrelia burgdorferi | |
JP5566684B2 (en) | Recombinant toxin A / toxin B vaccine against Clostridium difficile | |
EP0478602B1 (en) | Expression of tetanus toxin fragment c | |
EP1709067B1 (en) | Lawsonia intracellularis subunit vaccines | |
JP4091112B2 (en) | Lipoprotein expression | |
JPH11500744A (en) | Transferrin receptor protein from Moraxella | |
CA2121121C (en) | Preparation of recombinant borrelia proteins | |
WO2002016422A2 (en) | Recombinant constructs of borrelia burgdorferi | |
JP3236610B2 (en) | Swine pleural pneumonia vaccine | |
Cullen et al. | Construction and evaluation of a plasmid vector for the expression of recombinant lipoproteins in Escherichia coli | |
Schmidt et al. | Gal-Gal pyelonephritis Escherichia coli pili linear immunogenic and antigenic epitopes. | |
AU7514494A (en) | Method for expression and purification of p2 protein from haemophilus influenzae type b | |
JPH11507827A (en) | Botulinum toxin type F and uses thereof | |
US7794734B2 (en) | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever | |
WO1990015132A2 (en) | Cloned treponema hyodysenteriae endoflagellar antigen | |
CA2281913A1 (en) | A vaccine against piscirickettsia salmonis based on a recombinant 17 kd protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2121121 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 941749 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992922390 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992922390 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992922390 Country of ref document: EP |